An FDA panel's discussion on antidepressants during pregnancy sparked controversy, with psychiatrists criticizing the panel's emphasis on unsubstantiated risks and lack of balanced viewpoints. The panel, featuring several non-US experts, largely contradicted medical consensus on SSRI safety, downplaying their effectiveness and highlighting potential risks like autism and birth defects, claims disputed by many experts. Critics cited the panel's one-sided nature and concerns that the discussion could lead to stricter regulations hindering access to necessary medication for pregnant women experiencing depression. The FDA defended the panel's composition and stated a commitment to evidence-based policy.

Prepared by Olivia Bennett and reviewed by editorial team.